logo
  

Safran FY20 Profit Down, Proposes Dividend; Sees Higher Margin, Lower Organic Revenues In FY21

French Aerospace company Safran (SAF.PA,0IU8.L,SAFRF.PK) reported Thursday that its fiscal 2020 consolidated profit attributable to owners of the parent was 352 million euros.

Adjusted net income - Group share was 844 million euros or 1.92 euros per share, compared to last year's 2.67 billion euros or 6.13 euros per share.

Consolidated recurring operating income was 1.39 billion euros. Adjusted recurring operating income fell 56 percent from last year to 1.69 billion euros.

Group operating margin was 10.2 percent, down from 15.5 percent in the year ago period.

Consolidated revenue was 16.63 billion euros.

Adjusted revenue fell 33 percent to 16.50 billion euros from 24.64 billion euros. Revenues were down 32.5 percent on an organic basis.

In the fourth-quarter sales decreased 32.5 percent on a reported basis and 30.1 percent organically to 4.35 billion euros.

Further, the company announced that a dividend payment of 0.43 euros per share will be proposed to the shareholders' vote at the Annual General Meeting on May 26, representing a 22 percent pay-out ratio

Looking ahead for fiscal 2021, Safran expects adjusted recurring operating margin to increase above 100 basis points, at least a 300 basis points improvement versus the prior year's second half.

Adjusted revenue is expected to decrease in the low single digits in organic terms.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwest Airlines' flights across the United States were delayed for hours on Monday evening due to technical issue in a weather information system by a third-party weather data provider. The airline later resumed flight operations after solving the issue, but there were delays. The United Kingdom's Competition and Markets Authority or CMA announced Tuesday that it has launched a market study into mobile ecosystems of technology giants Apple Inc. (AAPL) and Google, Inc. (GOOG) over concerns they have market power which is harming users and other businesses. The CMA is taking... Eli Lilly and Co. (LLY) announced Tuesday that it will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant), an orally disintegrating tablet patients take every other day. This study will help to advance the science of migraine treatment...
RELATED NEWS
Follow RTT